Loading
A phase 2/3 trial testing ICP-248 in chronic lymphocytic leukaemia, now recruiting.
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (APEX-03) is a phase 2/3 interventional study registered as NCT06378138, led by Beijing InnoCare Pharma Tech, and recruiting on the registry. Official title: A Phase II/III Study of ICP-248 in Combination With Orelabrutinib in Patients With Treatment-naïve Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Planned enrolment is 226 participants (estimated). The study started in 2024-05-15 and primary completion is expected in 2030-11-25. No results have been posted on ClinicalTrials.gov.
Shares ICP-248, InnoCare Pharma.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.